Literature DB >> 25231636

Early development of calcific aortic valve disease and left ventricular hypertrophy in a mouse model of combined dyslipidemia and type 2 diabetes mellitus.

Khai Le Quang1, Rihab Bouchareb1, Dominic Lachance1, Marc-André Laplante1, Diala El Husseini1, Marie-Chloé Boulanger1, Dominique Fournier1, Xiang Ping Fang1, Rita Kohen Avramoglu1, Philippe Pibarot1, Yves Deshaies1, Gary Sweeney1, Patrick Mathieu1, André Marette2.   

Abstract

OBJECTIVE: This study aimed to determine the potential impact of type 2 diabetes mellitus on left ventricular dysfunction and the development of calcified aortic valve disease using a dyslipidemic mouse model prone to developing type 2 diabetes mellitus. APPROACH AND
RESULTS: When compared with nondiabetic LDLr(-/-)/ApoB(100/100), diabetic LDLr(-/-)/ApoB(100/100)/IGF-II mice exhibited similar dyslipidemia and obesity but developed type 2 diabetes mellitus when fed a high-fat/sucrose/cholesterol diet for 6 months. LDLr(-/-)/ApoB(100/100)/IGF-II mice showed left ventricular hypertrophy versus C57BL6 but not LDLr(-/-)/ApoB(100/100) mice. Transthoracic echocardiography revealed significant reductions in both left ventricular systolic fractional shortening and diastolic function in high-fat/sucrose/cholesterol fed LDLr(-/-)/ApoB(100/100)/IGF-II mice when compared with LDLr(-/-)/ApoB(100/100). Importantly, we found that peak aortic jet velocity was significantly increased in LDLr(-/-)/ApoB(100/100)/IGF-II mice versus LDLr(-/-)/ApoB(100/100) animals on the high-fat/sucrose/cholesterol diet. Microtomography scans and Alizarin red staining indicated calcification in the aortic valves, whereas electron microscopy and energy dispersive x-ray spectroscopy further revealed mineralization of the aortic leaflets and the presence of inflammatory infiltrates in diabetic mice. Studies showed upregulation of hypertrophic genes (anp, bnp, b-mhc) in myocardial tissues and of osteogenic genes (spp1, bglap, runx2) in aortic tissues of diabetic mice.
CONCLUSIONS: We have established the diabetes mellitus -prone LDLr(-/-)/ApoB(100/100)/IGF-II mouse as a new model of calcified aortic valve disease. Our results are consistent with the growing body of clinical evidence that the dysmetabolic state of type 2 diabetes mellitus contributes to early mineralization of the aortic valve and calcified aortic valve disease pathogenesis.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve stenosis; diabetes mellitus, type 2; inflammation; obesity

Mesh:

Substances:

Year:  2014        PMID: 25231636     DOI: 10.1161/ATVBAHA.114.304205

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  20 in total

1.  Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis.

Authors:  Rihab Bouchareb; Marie-Chloé Boulanger; Lionel Tastet; Ghada Mkannez; Mohamed J Nsaibia; Fayez Hadji; Abdellaziz Dahou; Younes Messadeq; Benoit J Arsenault; Philippe Pibarot; Yohan Bossé; André Marette; Patrick Mathieu
Journal:  Eur Heart J       Date:  2019-05-01       Impact factor: 29.983

2.  Histopathological assessment of calcification and inflammation of calcific aortic valves from patients with and without diabetes mellitus.

Authors:  Josephin Mosch; Christian A Gleissner; Simon Body; Elena Aikawa
Journal:  Histol Histopathol       Date:  2016-06-29       Impact factor: 2.303

3.  Bidirectional Translation in Cardiovascular Calcification.

Authors:  Cynthia St Hilaire; Marcel Liberman; Jordan D Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03       Impact factor: 8.311

4.  Inactivation of platelet-derived TGF-β1 attenuates aortic stenosis progression in a robust murine model.

Authors:  Rohan Varshney; Brennah Murphy; Sean Woolington; Shahrouz Ghafoory; Sixia Chen; Tyler Robison; Jasimuddin Ahamed
Journal:  Blood Adv       Date:  2019-03-12

5.  Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr-/-ApoB100/100 mouse model.

Authors:  Marta Scatena; Melissa F Jackson; Mei Y Speer; Elizabeth M Leaf; Mary C Wallingford; Cecilia M Giachelli
Journal:  Cardiovasc Pathol       Date:  2018-02-15       Impact factor: 2.185

6.  Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease.

Authors:  Sandra Guauque-Olarte; David Messika-Zeitoun; Arnaud Droit; Maxime Lamontagne; Joël Tremblay-Marchand; Emilie Lavoie-Charland; Nathalie Gaudreault; Benoit J Arsenault; Marie-Pierre Dubé; Jean-Claude Tardif; Simon C Body; Jonathan G Seidman; Catherine Boileau; Patrick Mathieu; Philippe Pibarot; Yohan Bossé
Journal:  Circ Cardiovasc Genet       Date:  2015-11-09

7.  CAVD: civilization aortic valve disease.

Authors:  Patrick Mathieu; Benoit J Arsenault
Journal:  Eur Heart J       Date:  2017-07-21       Impact factor: 29.983

8.  OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway.

Authors:  Mohamed Jalloul Nsaibia; Marie-Chloé Boulanger; Rihab Bouchareb; Ghada Mkannez; Khai Le Quang; Fayez Hadji; Deborah Argaud; Abdellaziz Dahou; Yohan Bossé; Marlys L Koschinsky; Philippe Pibarot; Benoit J Arsenault; André Marette; Patrick Mathieu
Journal:  Cardiovasc Res       Date:  2017-09-01       Impact factor: 10.787

9.  Speckle tracking echocardiography in the diagnosis of early left ventricular systolic dysfunction in type II diabetic mice.

Authors:  Rong-juan Li; Jiao Yang; Ya Yang; Ning Ma; Bo Jiang; Qi-wei Sun; Yi-jia Li
Journal:  BMC Cardiovasc Disord       Date:  2014-10-08       Impact factor: 2.298

10.  Local Application of Leptin Antagonist Attenuates Angiotensin II-Induced Ascending Aortic Aneurysm and Cardiac Remodeling.

Authors:  Danny Ben-Zvi; Naphtali Savion; Frank Kolodgie; Amos Simon; Sudeshna Fisch; Katrin Schäfer; Noa Bachner-Hinenzon; Xin Cao; Arieh Gertler; Gili Solomon; Erez Kachel; Ehud Raanani; Jacob Lavee; Shlomo Kotev Emeth; Renu Virmani; Frederick J Schoen; Jacob Schneiderman
Journal:  J Am Heart Assoc       Date:  2016-05-03       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.